Preface.

Area of Science:

• Urology
• Infectious Diseases
• Pharmacology

Background:

• Lower urinary tract infections (UTIs) are a common condition, accounting for significant general practitioner consultations and antibiotic prescriptions.
• Uropathogenic bacteria are developing resistance to widely used antibiotics like trimethoprim and ampicillin, often exceeding 30-50% resistance rates.
• Rapid development of resistance to fluoroquinolones, a common alternative, poses further treatment challenges.

Purpose of the Study:

• To review current perspectives on the diagnosis and treatment of UTIs in light of evolving microbial resistance patterns.
• To reevaluate treatment options for UTIs, considering the challenges posed by antimicrobial resistance.
• To assess the potential role of pivmecillinam in managing UTIs.

Main Methods:

• The supplement is based on papers presented at a meeting in Vienna, Austria, sponsored by Leo Pharmaceutical Laboratories.
• It synthesizes current views on UTI diagnosis and treatment.
• Clinical data and pharmacological properties of pivmecillinam were considered.

Main Results:

• Antibiotic resistance to common UTI treatments is high.
• Fluoroquinolone resistance can emerge rapidly.
• Pivmecillinam exhibits a novel mode of action, rapid bacterial penetration, and lower affinity for beta-lactamases.

Conclusions:

• Pivmecillinam's spectrum of activity and safety profile make it a suitable candidate for UTI treatment.
• Long-term experience in several countries supports the efficacy of pivmecillinam.
• Reconsideration of pivmecillinam's role in UTI treatment is warranted.